Over the last 7 days, the Biotech industry has dropped 8.2%, driven by pullbacks in Akeso and Innovent Biologics of 7.5% and 5.3%, respectively. On the other hand Biocytogen Pharmaceuticals (Beijing) is actually up 17%. Overall the industry is down 47% in 12 months. As for the next few years, earnings are expected to grow by 36% per annum.
Has the Hong Kong Biotech Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Tue, 23 Apr 2024 | HK$315.9b | HK$49.5b | -HK$19,910,409,871.62 | 10.8x | -15.9x | 6.4x |
Thu, 21 Mar 2024 | HK$363.4b | HK$47.8b | -HK$20,968,633,010.96 | 17.5x | -17.3x | 7.6x |
Sat, 17 Feb 2024 | HK$337.6b | HK$47.2b | -HK$20,382,504,617.35 | 16.3x | -16.6x | 7.2x |
Mon, 15 Jan 2024 | HK$381.0b | HK$46.9b | -HK$20,252,418,110.00 | 17.7x | -18.8x | 8.1x |
Wed, 13 Dec 2023 | HK$401.1b | HK$46.8b | -HK$20,200,802,361.00 | 17.9x | -19.9x | 8.6x |
Fri, 10 Nov 2023 | HK$421.8b | HK$45.2b | -HK$18,930,524,594.00 | 13.5x | -22.3x | 9.3x |
Sun, 08 Oct 2023 | HK$388.5b | HK$45.0b | -HK$19,137,116,705.00 | 13.8x | -20.3x | 8.6x |
Tue, 05 Sep 2023 | HK$412.3b | HK$45.1b | -HK$16,929,241,645.00 | 15.1x | -24.4x | 9.1x |
Thu, 03 Aug 2023 | HK$397.0b | HK$35.5b | -HK$23,337,130,199.00 | 22x | -17x | 11.2x |
Sat, 01 Jul 2023 | HK$391.5b | HK$35.2b | -HK$23,144,115,321.00 | 25.3x | -16.9x | 11.1x |
Mon, 29 May 2023 | HK$418.5b | HK$36.0b | -HK$23,771,398,625.00 | 29.5x | -17.6x | 11.6x |
Wed, 26 Apr 2023 | HK$437.1b | HK$36.8b | -HK$24,032,083,790.00 | 18.6x | -18.2x | 11.9x |
Fri, 24 Mar 2023 | HK$429.7b | HK$35.0b | -HK$36,661,632,123.00 | 22.5x | -11.7x | 12.3x |
Sun, 19 Feb 2023 | HK$415.4b | HK$34.6b | -HK$34,907,192,228.00 | 32.6x | -11.9x | 12x |
Tue, 17 Jan 2023 | HK$468.0b | HK$35.0b | -HK$35,421,330,962.00 | 32.6x | -13.2x | 13.4x |
Thu, 15 Dec 2022 | HK$402.8b | HK$33.6b | -HK$33,929,185,420.00 | 25.7x | -11.9x | 12x |
Sat, 12 Nov 2022 | HK$351.8b | HK$33.7b | -HK$32,367,923,461.00 | 17.3x | -10.9x | 10.5x |
Mon, 10 Oct 2022 | HK$296.0b | HK$34.0b | -HK$32,532,101,794.00 | 16.4x | -9.1x | 8.7x |
Wed, 07 Sep 2022 | HK$320.5b | HK$34.4b | -HK$33,730,074,655.00 | 16.5x | -9.5x | 9.3x |
Fri, 05 Aug 2022 | HK$321.0b | HK$32.8b | -HK$46,309,057,875.00 | 12.1x | -6.9x | 9.8x |
Sun, 03 Jul 2022 | HK$368.6b | HK$33.1b | -HK$46,627,164,079.00 | 15.1x | -7.9x | 11.1x |
Tue, 31 May 2022 | HK$321.7b | HK$34.1b | -HK$45,954,938,846.00 | 13x | -7x | 9.4x |
Thu, 28 Apr 2022 | HK$319.9b | HK$35.6b | -HK$45,008,839,288.00 | 12.8x | -7.1x | 9x |
Sat, 26 Mar 2022 | HK$334.0b | HK$36.1b | -HK$38,675,782,158.00 | 13.4x | -8.6x | 9.3x |
Mon, 21 Feb 2022 | HK$315.1b | HK$31.3b | -HK$32,034,553,209.00 | 12.4x | -9.8x | 10.1x |
Wed, 19 Jan 2022 | HK$381.4b | HK$31.1b | -HK$31,891,209,285.00 | 13.2x | -12x | 12.2x |
Fri, 17 Dec 2021 | HK$442.9b | HK$31.1b | -HK$31,844,824,921.00 | 13.4x | -13.9x | 14.2x |
Sun, 14 Nov 2021 | HK$489.1b | HK$31.0b | -HK$31,744,501,684.00 | 14.4x | -15.4x | 15.8x |
Tue, 12 Oct 2021 | HK$498.7b | HK$30.5b | -HK$31,547,002,088.00 | 14.8x | -15.8x | 16.3x |
Thu, 09 Sep 2021 | HK$520.3b | HK$30.4b | -HK$31,412,511,864.39 | 17.5x | -16.6x | 17.1x |
Sat, 07 Aug 2021 | HK$541.3b | HK$30.2b | -HK$32,058,827,347.35 | 13.6x | -16.9x | 17.9x |
Fri, 30 Apr 2021 | HK$572.9b | HK$27.8b | -HK$26,637,487,691.09 | 16.9x | -21.5x | 20.6x |
-21.5x
Which industries have driven the changes within the Hong Kong Healthcare industry?
HK Market | -0.66% | |
Healthcare | -4.61% | |
Biotech | -8.19% | |
Biotech | -8.19% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$147.80 | 11.5% +HK$3.4b | n/a | PS19.4x | |
1801 Innovent Biologics | HK$36.15 | 4.2% +HK$2.4b | -3.2% | PS8.7x | |
9995 RemeGen | HK$30.00 | 11.1% +HK$1.6b | -36.4% | PS13.8x | |
2480 Beijing Luzhu Biotechnology | HK$23.00 | 16.9% +HK$672.1m | n/a | PB4.2x | |
2162 Keymed Biosciences | HK$32.30 | 7.1% +HK$594.9m | -47.6% | PS23.3x |